Navigation Links
Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
Date:10/10/2010

SAN FRANCISCO, CAOctober 10, 2010Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

More than 160 million people are infected throughout the world, and no vaccine is available to prevent further spread of the disease. Current treatments are not effective against the most common strains in the US and Europe. The study, published in the journal Nature Medicine, shows that the enzyme DGAT1 is a key factor in HCV infection. With several potential DGAT1 inhibitors already in the drug-development pipeline, a treatment for HCV may be possible in the near future.

"Our results reveal a potential 'Achilles heel' for HCV infection," said Melanie Ott, MD, PhD, senior author on the study. "Several DGAT1 inhibitors are already in early clinical trials to treat obesity-associated diseases. They might also work against HCV."

At first glance, the HCV lifecycle is fairly simple. The virus enters the cell. One large protein is produced and cut into several smaller viral enzymes and proteins that build the virus. The RNA genome is copied, and the new RNAs and structural proteins are used to make new virus particles that are released into the blood stream for to infect more cells. These processes were thought to occur at specialized membranes inside the cell. However, recently it has been shown that fat droplets are critically involved.

Fat droplets, which store fat in cells, have become a hot new topic in biology. DGAT1 is one of the enzymes that help to form fat droplets. The Gladstone team, led by Eva Herker, PhD, discovered that HCV infection and viral particle production are severely impaired in liver cells that lack DGAT1 activity.

"DGAT enzymes produce the fat that is stored in the droplets that are important for HCV replication, so we wondered if inhibiting those enzymes might disrupt the viral life cycle," said Dr. Herker. "We found that HCV specifically relies on one DGAT enzymes, DGAT1. When we inhibit DGAT1 with a drug, the liver still produces fat droplets through another DGAT enzyme but these droplets cannot be used by HCV."

The team sought to identify which step in the HCV lifecycle requires DGAT1. They found that DGAT1 interacts with one viral protein, the viral nucleocapsid core protein, required for viral particle assembly. The core protein normally associates with the surface of fat droplets but cannot do so when DGAT1 is inhibited or missing in infected cells.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstones Shinya Yamanaka wins Kyoto prize
2. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
3. Gladstones Shinya Yamanaka wins Lasker Award
4. Gladstone scientists identify key factors in heart cell creation
5. Gladstone scientists reveal key enzyme in fat absorption
6. Gladstone scientists reveal that fat synthesizing enzyme is key to healthy skin and hair
7. Scientists watch cell-shape process for first time
8. Studying illnesses caused by worms: Scientists are learning how immune cells communicate
9. Scientists trick bacteria with small molecules
10. DFG awards 4 young scientists 2010 Bernd Rendel Prize
11. Scripps Research scientists develop novel test that identifies river blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... ... February 17, 2017 , ... ... and DJI, the world’s leading maker of unmanned aircraft systems (UAS), are launching ... officers to use drones effectively, and support educational outreach efforts. , AMA and ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure ... was performed on a 55-year-old practicing female physician suffering from degenerative disc disease ...
Breaking Biology Technology: